Impact of Antibiotic Choice on Pneumonia Readmission Rates.
There are many patient and institutional variables associated with a higher risk of rehospitalization within 30 days of an admission for community-acquired pneumonia. However, less is known regarding the impact of antibiotics. A retrospective cohort study of 271 patients was performed to determine whether, when controlling for known factors for readmission, the choice of antibiotic affects 30-day rehospitalization after an index admission of pneumonia. Multivariate logistic regression analysis was performed to determine correlation between antibiotic choice and readmission rates. Empiric tobramycin was associated with a 31.2% increased risk of readmission for any reason (P < 0.01). Empiric and treatment aztreonam were associated with a 13.7% and 13.5% increased risk of readmission with recurrent pneumonia, respectively (both P < 0.05). Further research evaluating these associations is warranted.
1Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Rockford, IL; and 2Department of Economics, Michigan State University, East Lansing, MI.
Alice N
AN
Hemenway
Michael A
MA
Naretta
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001398:Aztreonam / Q000627:therapeutic use; D002755:Choice Behavior; D000066491:Clinical Decision-Making; D017714:Community-Acquired Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007902:Length of Stay / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D010359:Patient Readmission / Q000706:statistics & numerical data*; D011014:Pneumonia / Q000188:drug therapy*; D012189:Retrospective Studies; D012307:Risk Factors; D014031:Tobramycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D001398:Aztreonam; D014031:Tobramycin